Noncytotoxic differentiation treatment of renal cell cancer

Cancer Research

Volumn 71, Issue 4, 2011, Pages 1431-1441

  Negrotto, Soledad ^a   Hu, Zhenbo ^a   Alcazar, Oscar ^a   Ng, Kwok Peng ^a   Triozzi, Pierre ^a   Lindner, Daniel ^a   Rini, Brian ^a   Saunthararajah, Yogen ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA METHYLTRANSFERASE 1; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PROTEIN P53;

APOPTOSIS; ARTICLE; BLOOD CELL COUNT; CANCER CELL; CELL DIFFERENTIATION; CELL DIVISION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MARKER; DNA DAMAGE; DRUG EFFICACY; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CARCINOMA, RENAL CELL; CELL AGING; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXINS; DNA DAMAGE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951846889     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2422     Document Type: Article

References (47)

1. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009;10:992-1000.
2. Hagiwara H, Sato H, Ohde Y, Takano Y, Seki T, Ariga T, et al. 5-Aza-2′-deoxycytidine suppresses human renal carcinoma cell growth in a xenograft model via up-regulation of the connexin 32 gene. Br J Pharmacol 2008;153:1373-81. (Pubitemid 351481519)
3. Alleman WG, Tabios RL, Chandramouli GV, Aprelikova ON, Torres-Cabala C, Mendoza A, et al. The in vitro and in vivo effects of reexpressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-20-deoxycytidine. Clin Cancer Res 2004;10:7011-21. (Pubitemid 39383053)
4. Coral S, Sigalotti L, Altomonte M, Engelsberg A, Colizzi F, Cattarossi I, et al. 5-Aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002;8:2690-5. (Pubitemid 34856358)
5. Pili R. Recent investigations of histone deacetylase inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2009;7:252-4.
6. Tuma RS. Epigenetic therapies move into new territory, but how exactly do they work?J Natl Cancer Inst 2009;101:1300-1.
7. Haaf T. The effects of 5-azacytidine and 5-azadeoxycytidine on chromosome structure and function: implications for methylation-associated cellular processes. Pharmacol Ther 1995;65:19-46. (Pubitemid 24381835)
8. Covey JM, D'Incalci M, Tilchen EJ, Zaharko DS, Kohn KW. Differences in DNA damage produced by incorporation of 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 1986;46:5511-7. (Pubitemid 17177937)
9. Schermelleh L, Haemmer A, Spada F, Rosing N, Meilinger D, Rothbauer U, et al. Dynamics of Dnmt1 interaction with the replication machinery and its role in postreplicative maintenance of DNA methylation. Nucleic Acids Res 2007;35:4301-2.
10. Saunthararajah Y, Hillery CA, Lavelle D, Molokie R, Dorn L, Bressler L, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003;102:3865-70. (Pubitemid 37486964)
11. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, et al. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009;4:e4563.
12. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, et al. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006;12:4619-27. (Pubitemid 44297813)
13. Milhem M, Mahmud N, Lavelle D, Araki H, Desimone J, Saunthararajah Y, et al. Modification of hematopoietic stem cell fate by 5-aza-2′deoxycytidine and trichostatin A. Blood 2004;103:4102-10. (Pubitemid 38685350)
14. Chung YS, Kim HJ, Kim TM, Hong SH, Kwon KR, An S, et al. Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticityBlood 2009;114:4968-78.
15. Suzuki M, Harashima A, Okochi A, Yamamoto M, Nakamura S, Motoda R, et al. 5-Azacytidine supports the long-term repopulating activity of cord blood CD34(+) cells. Am J Hematol 2004;77:313-5. (Pubitemid 39430714)
16. Hu Z, Negrotto S, Gu X, Mahfouz R, Ng KP, Ebrahem Q, et al. Maintains hematopoietic precursor self-renewal by preventing repression of stem cell genes by a differentiation-inducing stimulus. Mol Cancer Ther 2010;9:1536-43.
17. Gurova KV, Hill JE, Razorenova OV, Chumakov PM, Gudkov AV. p53 pathway in renal cell carcinoma is repressed by a dominant mechanism. Cancer Res 2004;64:1951-8. (Pubitemid 38339439)
18. Roberts AM, Watson IR, Evans AJ, Foster DA, Irwin MS, Ohh M. Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells. Cancer Res 2009;69:9056-64.
19. Ebert T, Bander NH, Finstad CL, Ramsawak RD, Old LJ. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531-6. (Pubitemid 20303015)
20. Bauer JA, Morrison BH, Grane RW, Jacobs BS, Borden EC, Lindner DJ. IFN-alpha2b and thalidomide synergistically inhibit tumorinduced angiogenesis. J Interferon Cytokine Res 2003;23:3-10. (Pubitemid 36308056)
21. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A 2007;104:13086-91. (Pubitemid 351737597)
22. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20. (Pubitemid 13179545)
23. Maegawa S, Hinkal G, Kim HS, Shen L, Zhang L, Zhang J, et al. Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res 2010;20:332-40.
24. Rogstad DK, Herring JL, Theruvathu JA, Burdzy A, Perry CC, Neidigh JW, et al. Chemical decomposition of 5-aza-2'-deoxycytidine (decitabine): kinetic analyses and identification of products by NMR, HPLC, and mass spectrometry. Chem Res Toxicol 2009;22:1194-204.
25. Narita M, Nunez S, Heard E, Narita M, Lin AW, Hearn SA, et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 2003;113:703-16. (Pubitemid 36724935)
26. Tavares TS, Nanus D, Yang XJ, Gudas LJ. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther 2008;7:1607-18.
27. Hosono S, Luo X, Hyink DP, Schnapp LM, Wilson PD, Burrow CR, et al. WT1 expression induces features of renal epithelial differentiation in mesenchymal fibroblasts. Oncogene 1999;18:417-27. (Pubitemid 29060617)
28. Li CM, Guo M, Borczuk A, Powell CA, Wei M, Thaker HM, et al. Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol 2002;160:2181-90. (Pubitemid 34663409)
29. Parviz F,Matullo C,GarrisonWD,Savatski L,AdamsonJW, NingG, et al. Hepatocyte nuclear factor 4alpha controls the development of a hepatic epithelium and liver morphogenesis. Nat Genet 2003;34:292-6.
30. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148-57.
31. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001;97:3589-95.
32. Andersen MK, Christiansen DH, Kirchhoff M, Pedersen-Bjergaard J. Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents. Genes Chromosomes Cancer 2001;31:33-41. (Pubitemid 32274130)
33. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005;43:227-38. (Pubitemid 40726868)
34. Akashi K, He X, Chen J, Iwasaki H, Niu C, Steenhard B, et al. Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood 2003;101:383-9.
35. Suarez L, Vidriales MB, Garcia-Larana J, Sanz G, Moreno MJ, Lopez A, et al. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes. Clin Cancer Res 2004;10:7599-606. (Pubitemid 39557522)
36. Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-87.
37. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-75. (Pubitemid 44572384)
38. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
39. Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996;85:721-32.
40. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996;85:733-44.
41. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.
42. Cheng T, Rodrigues N, Dombkowski D, Stier S, Scadden DT. Stem cell repopulation efficiency but not pool size is governed by p27(kip1). Nat Med 2000;6:1235-40.
43. Hay ED. An overview of epithelio-mesenchymal transformation. Acta Anat 1995;154:8-20.
44. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463:360-3.
45. Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, et al. Clinical effectiveness of decitabine in severe sickle cell disease. Br J Haematol 2008;141:126-9. (Pubitemid 351347540)
46. Sorm F, Vesely J. Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 1968;15:339-43.
47. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 1987;23:1921-4. (Pubitemid 18013335)